ONTRACK'S URINE TEST
Our urine test is designed to reduce the burden on patients and healthcare systems by supporting more informed decisions on prostate biopsy and active surveillance of indolent prostate cancer, while decreasing associated costs
PIONEERING NON-INVASIVE DIAGNOSTIC TESTS FOR CANCER
ONTRACK Biomedical AG can generate high-affinity monoclonal antibodies with broad epitope diversity, enabling highly sensitive and specific immunoassays that detect low-abundance proteins without sample processing or stabilization. Our technology is particularly suitable for non-invasive tests, supporting the quantification of novel biomarkers in challenging specimens, such as urine, and applicable across medical fields.
Our scientific publications:
https://doi.org/10.1038/s41598-024-68026-1
Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer. Cancers 2022, 14(5), 1135; https://doi.org/10.3390/cancers14051135.
Core technology
ONtrack Biomedical's innovative method is based on the generation and selection of high-affinity monoclonal antibodies against any specific target. Negative selection is applied to eliminate off-target binding, ensuring high assay specificity.
Multiplex Capability
Our technology is designed to enable multi-plex immunoassays that simultaneously quantify multiple target biomarkers in a single test with high analytical sensitivity. ONtrack's prostate cancer urine test is being developed to leverage this capability, targeting a panel of six biomarkers for enhanced diagnostic performance.
Novel biomarkers discovery: Proban
ONtrack Biomedical has developed a unique strategy for the discovery of novel biomarkers in non-invasive biological samples, applicable to any disease and biological material. The first application is ONtrack's prostate cancer urine test, based on the identification of 60 novel urinary protein biomarkers (patent filed) for prostate cancer diagnosis (Alijaj et al, Cancers 2022; Pavlovic et al, Scientific Reports 2024).
DO YOU NEED A COMPANION IVD FOR YOUR DRUG?
ONtrack's biomarker discovery platform has identified urinary protein targets currently under active drug development. This creates an opportunity to develop companion diagnostics in urine — enabling patient selection for clinical trials and monitoring of treatment response — leveraging the same ELISA-based technology platform underlying ONtrack's prostate cancer urine test